Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis

Cytokine

Volumn 78, Issue , 2016, Pages 87-93

  Murota, Atsuko ^a   Suzuki, Katsuya ^a   Kassai, Yoshiaki ^b   Miyazaki, Takahiro ^b   Morita, Rimpei ^a   Kondo, Yasushi ^a   Takeshita, Masaru ^a   Niki, Yasuo ^a   Yoshimura, Akihiko ^a   Takeuchi, Tsutomu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Biomarker; Interleukin 16; Proteomics; Rheumatoid arthritis; Serum protein

Indexed keywords

ABATACEPT; BIOLOGICAL MARKER; INTERLEUKIN 16; METHOTREXATE; STROMELYSIN; TOCILIZUMAB; ANTIRHEUMATIC AGENT; INFLIXIMAB; MMP3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PLASMA PROTEIN;

ADULT; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RELIABILITY; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYNOVIAL FLUID LEVEL; SYNOVITIS; AGED; ARTHRITIS, RHEUMATOID; BLOOD; ERYTHROCYTE SEDIMENTATION RATE; IMMUNOLOGY; MIDDLE AGED; STATISTICS; TREATMENT OUTCOME;

ABATACEPT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; BLOOD PROTEINS; BLOOD SEDIMENTATION; FEMALE; HUMANS; INFLIXIMAB; INTERLEUKIN-16; MALE; MATRIX METALLOPROTEINASE 3; METHOTREXATE; MIDDLE AGED; PROTEOMICS; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 84949595550     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.12.002     Document Type: Article

References (50)

1. McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. New Engl. J. Med. 2011, 365:2205-2219.
2. Smolen J.S., Landewé R., Breedveld F.C., Buch M., Burmester G., Dougados M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 2014, 73:492-509.
3. Lipsky P.E., van der Heijde D.M., St.Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. New Engl. J. Med. 2000, 343:1594-1602.
4. Smolen J.S., Avila J.C., Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann. Rheum. Dis. 2012, 71:687-693.
5. Niu X., Chen G. Clinical biomarkers and pathogenic-related cytokines in rheumatoid arthritis. J. Immunol. Res. 2014, 698192.
6. Klimiuk P.A., Sierakowski S., Latosiewicz R., Cylwik B., Skowronski J., Chwiecko J. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis. Rheumatology (Oxford) 2002, 41:78-87.
7. Posthumus M.D., Limburg P.C., Westra J., Cats H.A., Stewart R.E., van Leeuwen M.A., et al. Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology 1999, 38:1081-1087.
8. Ribbens C., Martin y Porras M., Franchimont N., Kaiser M.J., Jaspar J.M., Damas P., et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann. Rheum. Dis. 2002, 61:161-166.
9. Komosinska-Vassev K., Olczyk P., Winsz-Szczotka K., Kuznik-Trocha K., Klimek K., Olczyk K. Age- and gender-dependent changes in connective tissue remodeling: physiological differences in circulating MMP-3, MMP-10, TIMP-1 and TIMP-2 level. Gerontology 2011, 57:44-52.
10. Kaneko A., Kida D., Saito K., Tsukamoto M., Sato T. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. Rheumatol. Int. 2012, 32:3631-3637.
11. Castro-Santos P., Laborde C.M., Díaz-Peña R. Genomics, proteomics and metabolomics: their emerging roles in the discovery and validation of rheumatoid arthritis biomarkers. Clin. Exp. Rheumatol. 2015, 33:279-286.
12. Mehan M.R., Ayers D., Thirstrup D., Xiong W., Ostroff R.M., Brody E.N., et al. Protein signature of lung cancer tissues. PLoS ONE 2012, 7:e35157.
13. De Groote M.A., Nahid P., Jarlsberg L., Johnson J.L., Weiner M., Muzanyi G., et al. Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS ONE 2013, 8:e61002.
14. Sattlecker M., Kiddle S.J., Newhouse S., Proitsi P., Nelson S., Williams S., et al. Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement. 2014, 10:724-734.
15. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31:315-324.
16. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 Rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010, 62:2569-2581.
17. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 2002, 61:554-558.
18. Shiboski S.C., Shiboski C.H., Criswell L., Baer A., Challacombe S., Lanfranchi H., et al. American college of rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International collaborative clinical alliance cohort. Arthritis Care Res. (Hoboken) 2012, 64:475-487.
19. Fujibayashi T., Sugai S., Miyasaka N., Hayashi Y., Tsubota K. Revised Japanese criteria for Sjögren's syndrome (1999): availability and validity. Mod. Rheumatol. 2004, 14:425-434.
20. Prevoo M.L., van't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38:44-48.
21. Smolen J.S., Breedveld F.C., Schiff M.H., Kalden J.R., Emery P., Eberl G., et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003, 42:244-257.
22. Aletaha D., Nell V.P., Stamm T., Uffmann M., Pflugbeil S., Machold K., et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res. Ther. 2005, 7:R796-R806.
23. Pincus T., Summey J.A., Soraci S.A., Wallston K.A., Hummon N.P. Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis Rheum. 1983, 26:1346-1353.
24. Benson M.D., Cohen A.S. Serum amyloid A protein in amyloidosis, rheumatic, and enoplastic diseases. Arthritis Rheum. 1979, 22:36-42.
25. Green M.J., Gough A.K., Devlin J., Smith J., Astin P., Taylor D., et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003, 42:83-88.
26. Meliconi R., Uguccioni M., Chieco-Bianchi F., Pitzalis C., Bowman S., Facchini A., et al. The role of interleukin-8 and other cytokines in the pathogenesis of Felty's syndrome. Clin. Exp. Rheumatol. 1995, 13:285-291.
27. Jose P.J., Moss I.K., Maini R.N., Williams T.J. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann. Rheum. Dis. 1990, 49:747-752.
28. Bartok B., Firestein G.S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol. Rev. 2010, 233:233-255.
29. Lard L.R., Roep B.O., Toes R.E., Huizinga T.W. Enhanced concentrations of interleukin 16 are associated with joint destruction in patients with rheumatoid arthritis. J. Rheumatol. 2004, 31:35-39.
30. Franz J.K., Kolb S.A., Hummel K.M., Lahrtz F., Neidhart M., Aicher W.K., et al. Interleukin-16, produced by synovial fibroblasts, mediates chemoattraction for CD4+ T lymphocytes in rheumatoid arthritis. Eur. J. Immunol. 1998, 28:2661-2671.
31. Kageyama Y., Takahashi M., Torikai E., Suzuki M., Ichikawa T., Nagafusa T., et al. Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin. Rheumatol. 2007, 26:505-509.
32. Martel-Pelletier J., McCollum R., Fujimoto N., Obata K., Cloutier J.M., Pelletier J.P. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab. Invest. 1994, 70:807-815.
33. Martel-Pelletier J., Welsch D.J., Pelletier J.P. Metalloproteases and inhibitors in arthritic diseases. Clin. Rheumatol. 2001, 15:805-829.
34. Hamakawa H., Takemura M., Sato M., Shinohe R., Koishi H., Furuta N., et al. Clinical significance of MMP-3 in patients with rheumatoid arthritis: comparison with other inflammatory markers (IL-6, IL-8). Rinsho Byori 2003, 51:13-18.
35. Xiangyang Z., Lutian Y., Lin Z., Liping X., Hui S., Jing L. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine 2012, 58:6-9.
36. Center D.M., Cruikshank W. Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated mononuclear cells. J. Immunol. 1982, 128:2563-2568.
37. Blaschke V., Reich K., Middel P., Letschert M., Sachse F., Harwix S., et al. Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides. J. Invest. Dermatol. 1999, 113:658-663.
38. Matsushita M., Hayashi T., Ando S., Sekigawa I., Iida N., Hashimoto H., et al. Changes of CD4/CD8 ratio and interleukin-16 in systemic lupus erythematosus. Clin. Rheumatol. 2000, 19:270-274.
39. Klimiuk P.A., Goronzy J.J., Weyand C.M. IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J. Immunol. 1999, 162:4293-4299.
40. Cho M.L., Jung Y.O., Kim K.W., Park M.K., Oh H.J., Ju J.H., Cho Y.G., Min J.K., Kim S.I., Park S.H., Kim H.Y. IL-17 induces the production of IL-16 in rheumatoid arthritis. Exp. Mol. Med. 2008, 40:237-245.
41. Laberge S., Ernst P., Ghaffar O., Cruikshank W.W., Kornfeld H., Center D.M., et al. Increased expression of interleukin-16 in bronchial mucosa of subjects with atopic asthma. Am. J. Respir. Cell Mol. Biol. 1997, 17:193-202.
42. Skundric D.S., Cai J., Cruikshank W.W., Gveric D. Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions. J. Neuroinflammation 2006, 26:3-15.
43. Keates A.C., Castagliuolo I., Cruickshank W.W., Qiu B., Arseneau K.O., Brazer W., et al. Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice. Gastroenterology 2000, 119:972-982.
44. Blaschke S., Schulz H., Schwarz G., Blaschke V., Müller G.A., Reuss-Borst M. Interleukin 16 expression in relation to disease activity in rheumatoid arthritis. J. Rheumatol. 2001, 28:12-21.
45. Kageyama Y., Ichikawa T., Nagafusa T., Torikai E., Shimazu M., Nagano A. Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis. Rheumatol. Int. 2007, 28:137-143.
46. Mihara M., Urakawa K., Takagi N., Moriya Y., Takeda Y. In vitro and in vivo biological activities of a novel nonpolyglutamable anti-folate, MX-68. Immunopharmacology 1996, 35:41-46.
47. Johnson L.F., Fuhrman C.L., Abelson H.T. Resistance of resting 3T6 mouse fibroblasts to methotrexate cytotoxicity. Cancer Res. 1978, 38:2408-2412.
48. Mihara M., Moriya Y., Kishimoto T., Ohsugi Y. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br. J. Rheumatol. 1995, 34:321-325.
49. Corrigall V.M., Solau-Gervais E., Panayi G.S. Lack of CD80 expression by fibroblast-like synoviocytes leading to anergy in T lymphocytes. Arthritis Rheum. 2000, 43:1606-1615.
50. Nishimoto N., Terao K., Mima T., Nakahara H., Takagi N., Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008, 112:3959-3964.